DescriptionSeveral studies have demonstrated that HHV-6 could be an environmental trigger of thyroid autoimmunity by showing high prevalence of the virus in the diseased tissues. HHV-6 possesses a range of immunomodulatory abilities and one of the modulation strategies it utilizes is virally encoded chemokine receptors. HHV-6 encodes two putative homologs of cellular G-protein-coupled receptors - U12 and U51. In vitro studies have shown that these two viral receptors can interact with cytokine and chemokine signaling. This study aimed to investigate the immunomodulating properties of HHV-6 in the development of autoimmune thyroid disease via the investigation of HHV-6 interaction with RANTES signaling pathway. Prior to this study, the presence of HHV-6 DNA, viral load, the expression of active infection markers and viral chemokine receptors was determined in patient tissue samples. The levels of of RANTES, IFN-γ and TNFα were determined in 109 patient and 27 blood donor plasma samples.
Conclusions: Autoimmune thyroiditis patient RANTES plasma levels were significantly lower compared to healthy blood donors. A potential link exists between RANTES level and viral load, as higher HHV-6 viral loads could be observed in patient with the lowest RANTES levels. HHV-6 could be able to disrupt RANTES production, as AIT patients had lower levels or RANTES, even with higher levels of RANTES inductive cytokines.
|Period||29 May 2021|
|Event title||12th International Congress on Autoimmunity|
|Degree of Recognition||International|
- thyroid autoimmunity